 |
|
Fluoroquinolone-Resistance in Neisseria gonorrhoeae, Hawaii, 1999, and Decreased Susceptibility to Azithromycin in N. gonorrhoeae, Missouri, 1999
Arch Dermatol. 2001;137:106-107.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
IN 1999, 360,076 cases of gonorrhea were reported in the United States.1 Gonorrhea is a major cause of pelvic inflammatory disease, often leading to ectopic pregnancy and infertility, and it can facilitate human immunodeficiency virus (HIV) transmission.2 During the 1980s, resistance to penicillin and tetracycline among gonococcal isolates became widespread; as a result, CDC recommended that other antimicrobial agents be used to treat gonorrhea. This report summarizes investigations of an increase in fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii and of a cluster of N. gonorrhoeae infections with decreased susceptibility to azithromycin in Missouri.
N. gonorrhoeae With Fluoroquinolone-Resistance, Hawaii
The susceptibility of N. gonorrhoeae to ciprofloxacin is used to assess susceptibility to all equivalent fluoroquinolone antimicrobials. The Hawaii Department of Health State Laboratory (HSL) routinely performs antimicrobial susceptibility testing on all gonococcal isolates identified by culture. HSL also submits gonococcal isolates from the Diamond Head Health Center STD and HIV Clinic in Honolulu, Hawaii, to the Gonococcal . . . [Full Text of this Article]
N. gonorrhoeae With Decreased Susceptibility to Azithromycin, Kansas City, Missouri
Reported by:
Editorial Note:
|
